The collaboration will develop advanced approaches to treating challenging bacterial infections and improving patient outcomes
Paldara Pharmaceuticals, a biotechnology company specialising in advancing a novel hydrogen drug delivery platform for bacteriophage therapeutics, has entered into an agreement with the Mayo Clinic to develop advanced approaches to treating challenging bacterial infections and improving patient outcomes.
Bacteriophages are naturally occurring, good viruses that can defend against and get rid of the targeted disease bacteria while leaving the healthy tissue intact.
The initiative will use Paldara's hydrogel platform, initially designed to deliver bacteriophages directly to sites of infection, particularly those that are resistant to current treatments. This platform addresses issues with current antimicrobial treatments by supporting localised application rather than intravenous delivery. Paldara’s shelf-stable encapsulation of bacteriophages also removes the need for cold chain storage.
Mayo Clinic’s physicians and microbiologists will offer clinical insight, translational methods, and research guidance through a know-how license agreement.
William Colton, CEO and founder of Paldara, said, “This collaboration is deeply personal to me. My grandmother survived the Holocaust, built a life in America, and raised our family – only to die from a drug-resistant staph infection after a routine hip replacement. We had no antibiotics left that could save her. That moment drives everything we do at Paldara. This agreement represents our commitment to change the odds for patients like her.”
